Diego Adrianzen-Herrera, MD, MS
@diegoah66.bsky.social
Associate Professor of Medicine @UVMLarnerMed | Hematologist-Oncologist @UVMMedCenter | #BloodCancer #OutcomesResearch | Peruvian 🇵🇪 https://uvmcommunity.uvm.edu/portal/uvmcc_members?cmd=memberbio&netid=dadrianz
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations www.nature.com/articles/s41...
Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations - Blood Cancer Journal
Blood Cancer Journal - Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations
nature.com
Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | New England Journal of Medicine www.nejm.org/doi/full/10....
Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | NEJM
Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%.
nejm.org
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers www.nature.com/articles/s41...
The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms - Leukemia
Leukemia - The evolving landscape of epigenetic target molecules and therapies in myeloid cancers: focus on acute myeloid leukemia and myeloproliferative neoplasms
nature.com
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin | Blood Advances | American Society of Hematology ashpublications.org/bloodadvance...
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin
Key PointsFLT3-ITD MRD identifies patients at high relapse risk after intensive chemotherapy with midostaurin.Conversion from FLT3-ITD MRDneg to FLT3-ITD M
ashpublications.org
How insurance companies degrade the patient-doctor relationship, by Helen Ouyang, my friend and exceptional physician-author gift link www.nytimes.com/2024/12/08/o... @nytopinion.nytimes.com
#myeloMATCH is the NCI’s #precisionmedicine trial in #myeloid cancer: advanced biomarker testing in newly diagnosed acute myeloid #leukemia (#AML) or #myelodysplastic syndrome (#MDS) & treatment substudies by the Alliance, Canadian Cancer Trials Group, @eaonc.bsky.social & SWOG. swog.org/myeloMATCH
8 days ago, ASH decided to join Bluesky. 🌤️ So far, we're enjoying fewer distractions & more meaningful connections. 💬 Engaging with our amazing #hematology and #hemeonc communities has never been easier. We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed #Hemesky
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine ashpublications.org/blood/articl...
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge
ashpublications.org
Venetoclax + HMA for previously untreated Higher-Risk Myelodysplastic Syndromes and genotype signatures onlinelibrary.wiley.com/doi/full/10....
Venetoclax and Hypomethylating Agent in Previously Untreated Higher‐Risk Myelodysplastic Syndromes and Genotype Signatures for Response and Prognosis: A Real‐World Study
Click on the article title to read more.
onlinelibrary.wiley.com
👇👇👇 Genetic risk stratification and outcomes in treatment-naive AML treated with venetoclax + azacitidine ashpublications.org/blood/articl...
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Key PointsELN 2017 and 2022 prognostic classifiers did not adequately stratify OS outcomes for patients with AML treated with venetoclax-azacitidine.A 4-ge
ashpublications.org
It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...
FDA approves revumenib for relapsed or refractory acute leukemia
On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.
fda.gov
Very interesting 👇👇
Lee Grimes Lab@leegrimeslab.bsky.social · 2y agoPrevious studies have shown self-reported Black patients have inferior treatment and survival outcomes compared to White patients, but why? Our work indicating that underlying genetics influence AML biology is now live at Nature Genetics. www.nature.com/articles/s41...
Not many papers change the way I think about AML, but this exceptional work shows how cell states and genetics intertwine to mediate venetoclax resistance, unifying previous studies by identifying RAS-mutated LSCs that are primed to produce myeloid cells #hemesky 🩸🧪 www.nature.com/articles/s41...
